EuropaWire2h
Novartis Acquires Anthos Therapeutics to Advance Abelacimab in Stroke and Thrombosis Prevention
Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...
Novartis signs agreement to acquire Anthos for $925m upfront
Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...
TMCnet1d
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Anthos is currently conducting a phase 3 clinical study in patients with atrial fibrillation with high risk for stroke or systemic embolism (LILAC-TIMI 76) as well as two phase 3 studies in patients ...
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in ...
A pioneering procedure for the treatment of atrial fibrillation
In February 2024, Corewell Health introduced pulsed field ablation, a treatment procedure significantly safer than previous AFib treatments, at several of its Michigan hospitals. PFA applies a ...
Alternative to blood thinners providing AFib patients the same protection from stroke
The Watchman device is providing protection from blood clots and strokes for those patients at risk because of their AFib.
EurekAlert!6d
Research unveils new strategies to tackle atrial fibrillation, a condition linked to stroke and dementia risks
A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and treating atrial fibrillation, a condition that significantly raises the risks ...